A US biotech company called AOBiome Therapeutics said that it has initiated a Phase 2 study of an ammonia oxidizing bacteria (AOB) nasal spray for the prevention of episodic migraine. According to AOBiome, the nasal spray, which contains a single strain of Nitrosomonas eutropha, is expected to repopulate the nasal microbiome where it will convert naturally occurring ammonia to nitric oxide.
The randomized, double-blind, Phase 2 safety, tolerability, and efficacy study is expected to enroll 303 episodic migraine patients who will receive one of two doses of AOB or vehicle.
AOBiome President and CEO Todd Krueger commented, “Initiation of our migraine study extends our AOB pipeline to a broad neurology indication for the first time. The trial also further builds on our capabilities in intranasal delivery, which has recently shown promising safety data in treating individuals with seasonal allergic rhinitis.”
Read the AOBiome press release.
